- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471236
Evaluation of the Agili-C Biphasic Implant in the Knee Joint
Evaluation of the Agili-C Bi-phasic Implant Performances in the Repair of Cartilage and Osteochondral Defects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zagreb, Croatia
- Clinical Hospital ''Sveti Duh''
-
-
-
-
-
Brno, Czechia
- Fakultní Nemocnice Brno
-
-
-
-
-
Budapest, Hungary
- Uzsoki Street Hospital
-
-
-
-
-
Bologna, Italy
- Rizzoli Orthopaedic Institute
-
-
-
-
-
Katowice, Poland
- Avimed Hospital
-
-
-
-
-
Timisoara, Romania
- County Hospital of Timisoara,
-
-
-
-
-
Belgrade, Serbia
- Institut Za Ortopediju "Banjica"
-
Novi Sad, Serbia
- Clinical Center of Vojvodina
-
-
-
-
-
Ljubljana, Slovenia
- University Medical Centre, Ljubljana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- 18 to 55 years
Symptomatic, single, focal, full or near full-thickness (ICRS cartilage defect description grades 3 and 4) chondral or osteochondral isolated lesion of the femoral condyle, trochlea or the tibial plateau
- Defect area is less than 2 cm² after debridement. The defect is completely surrounded on all sides by healthy cartilage.
- Osteochondral defect ICRS Cartilage defect description type 1, 2, 3, 4A. Maximal defect depth should be up to 3 millimeters.
- Primary or secondary articular cartilage repair.
- Knee is stable or can be stabilized as a concomitant procedure.
- Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits.
- Signed informed consent.
- Any misalignments should be fully corrected at the end of the operative procedure.
Exclusion Criteria
- Uncorrected axial misalignments >5° that cannot be corrected.
- Patellar cartilage defects or pathology.
- Meniscal resection of more than 50%, either in a previous procedure or concomitant with articular cartilage repair.
- Any tumor of the ipsilateral knee, any concurrent malignant tumor or any metastatic tumor in the past or in the present.
- Active acute or chronic infection of the treated knee.
- Inflammatory arthropathy or crystal-deposition arthropathy.
- Systemic cartilage and/or bone disorder; This implants integration is dependent on surrounding live bleeding bone; therefore it must not be implanted within sequestrated or necrotic bone.
- Bony defect depth over 3 millimeters.
- Body mass index >35.
- Asymptomatic articular cartilage defects.
- Bipolar articular cartilage defects.
- Osteoarthritis of the operated knee.
Oral medications such as systemic corticosteroid therapy taken less than one year prior to surgery or chemotherapy.
- Previous operative treatment of Arthroscopic marrow stimulation technique or cell therapy operated within the last 6 months
- Any previous operation of cartilage treatment within the last 6 months
- Patients who are sensitive to materials containing calcium carbonate or hyaluronate
- Pregnant women, women who plan to become pregnant and breastfeeding women.
- Evidence of any significant systemic disease (such as but not limited to HIV infection, hepatitis infection or HTLV infection), known coagulopathies, severe vascular or neurological disease or acute injury that might compromise the patient's welfare.
- Substance abuse or alcohol abuse.
- Participation in another clinical trials in parallel to this study.
- Type I diabetes.
- Unable to undergo MRI or X-ray.
- Any reasons making the patient a poor candidate in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Agili-c bi-phasic implant
mini-arthrotomy
|
The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone). The implant will be inserted gently in a pressed fit manner.
Other Names:
The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded. Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improvement in KOOS pain subscales
Time Frame: 24 months
|
The primary efficacy endpoint for this trial will be the change from baseline up to 24 months visit in pain score as measured by the KOOS pain subscale
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
KOOS total score
Time Frame: 24 months
|
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of SAE
Time Frame: 24 months
|
Complications and adverse events, device-related or not, will be evaluated over the course of the clinical trial, including subsequent surgical interventions
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elizaveta Kon, MD
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLN0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cartilage Diseases
-
Zimmer Orthobiologics, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
ISTO Technologies, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
Sewon Cellontech Co., Ltd.UnknownDefect of Articular Cartilage | Articular Cartilage Disorder of Knee | Degeneration; Articular Cartilage, KneeKorea, Republic of
-
BioPoly LLCCompletedCartilage Injury | Defect of Articular Cartilage | Cartilage DamageUnited Kingdom
-
Biosolution Co., Ltd.RecruitingArticular Cartilage Defect | Articular Cartilage DegenerationUnited States
-
Hyalex Orthopaedics, Inc.Recruiting
-
Keele UniversityRobert Jones and Agnes Hunt Orthopaedic and District NHS TrustCompletedCartilage Injury | Cartilage DamageUnited Kingdom
-
AlloSourceActive, not recruitingCartilage Injury | Cartilage DamageUnited States
-
AlloSourceTerminatedCartilage Injury | Cartilage DamageUnited States
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia
Clinical Trials on Agili-C Bi-phasic Implant
-
Cartiheal (2009) LtdActive, not recruitingCartilage or Osteochondral Defects in the Knee | Up to Moderate OsteoarthritisUnited States, Israel, Belgium, Italy, Serbia, Hungary, Poland, Romania
-
Cartiheal (2009) LtdCompletedCartilage or Osteochondral Defects in the KneeAustria, Belgium, Slovenia, Italy, Israel, Poland, Romania, Serbia
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimRecruiting
-
Boehringer IngelheimCompletedHealthyNetherlands
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted